Summary
Alzheimer's disease (AD) is the most common disease causing dementia. Today the clinical diagnosis of AD is made by way of exclusion, and no biochemical markers are available to assist the clinical diagnosis. We examined the potential of neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) as a diagnostic marker for AD. NSE was determined with a monoclonal antibody two-site immunoradiometric assay (IRMA) in serum (S) and cerebrospinal fluid (CSF) samples from 45 patients with “probable Alzheimer's disease (AD)”, 19 patients with vascular dementia (VAD) and 33 age-matched healthy individuals. There was no significant correlation between S-NSE and CSF-NSE, or between CSF/S albumin ratio and CSF-NSE, findings suggesting that the major portion of CSF-NSE is intrathecally produced and that analysis of CSF-NSE alone (without accompanying analysis of serum) is sufficient. CSF-NSE was significantly higher in the AD group (4.7±2.7 ng/mL; p<0.0001) and in VAD group (4.5±2.5 ng/mL; p<0.001) as compared with the control group (2.2±1.0 ng/mL), while it did not differ significantly between the AD and the VAD group. These findings suggest that CSF-NSE have a potential as a non-disease specific marker for the neuronal degeneration in dementia disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
APA (American Psychiatric Association) (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington DC
Blennow K, Wallin A, Gottfries CG (1990) Confusional symptomatology distinguishes early and late onset Alzheimer's disease. Aging 2: 395–401
Blennow K, Wallin A, Gottfries CG (1991) Presence of parietal lobe symptomatology distinguishes early and late onset Alzheimer's disease. Int J Geriatr Psychiat 6: 47–154
Blennow K, Wallin A (1992) Clinical heterogeneity of probable Alzheimer's disease. J Geriatr Psychiatry Neurol 5: 106–113
Cicero TJ, Cowan WM, Moore BW, Suntzeff V (1970) The cellular localisation of the two brain specific proteins, S-100 and 14-3-2. Brain Res 18: 25–34
Coleman PD, Flood DG (1987) Neuron numbers and dendrite extent in normal aging and Alzheimer's disease. Neurobiol Aging 8: 521–545
Cutler NR, Kay AD, Marangos PJ, Burg C (1986) Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer's disease. Arch Neurol 43: 153–154
Egan MF, El-Mallakh RS, Suddath RL, Lohr JB, Bracha HS, Wyatt RJ (1992) Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia. Psychiatry Res 43: 187–195
Folstein M, Folstein S, McHugh P (1975) “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198
Hachinski VC (1983) Differential diagnosis of Alzheimer's dementia: multi-infarct dementia. In: Reisberg B (ed) Alzheimer's disease. The Free Press, New York, pp 188–192
Hårdemark HG, Persson L, Bolander HG, Hillered L, Olsson Y, Påhlman S (1988) Neuronspecific enolase is a marker of cerebral ischaemia and infarct size in rat cerebrospinal fluid. Stroke 19: 1140–1144
Hårdemark HG, Ericsson N, Kotwica Z, Rundström G, Mendel-Hartvig I, Olsson Y, Påhlman S, Persson L (1989) S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischaemic brain damage. J Neurosurg 71: 727–731
Hay E, Royds JA, Davies-Jones GAB, Lewtas NA, Timperley WR, Taylor CB (1984) Cerebrospinal fluid enolase in stroke. J Neurol Neurosurg Psychiatry 47: 724–729
Jacobi C, Reiber H (1988) Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid. Clin Chim Acta 177: 49–54
Lishman WA (1987) Organic psychiatry, the psychological consequences of cerebral disorder, 2nd ed. Year Book Medical Publishers, Chicago, pp 371–385
Marangos PJ (1991) Neuron specific enolase as a clinical tool in neurologic and endocrine disease. In: Gratzl M, Langley K (eds) Markers for neural and endocrine cells: molecular and cell biology, diagnostic applications. Weinheim, WCH, pp 181–189
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939–944
Mokuno K, Kato K, Kawai K, Matsuoka Y, Yanagi T, Sobue I (1983) Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases J Neurol Sci 60: 443–451
Moore BW (1973) Brain specific proteins. In: Schneider DJ, Angeletti RH, Bradshaw RA, Grasso A, Moore BW (eds) Proteins of the nervous system. Raven Press, New York, pp 1–12
Parma AM, Marangos PJ, Goodwin FK (1981) A more sensitive radioimmunoassay for neuron-specific enolase suitable for cerebrospinal fluid determinations. J Neurochem 36: 1093–1096
Persson L, Hårdemark HG, Gustafsson J, Rundström G, Mendel-Hartvig I, Esscher T, Påhlman S (1987) S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18: 911–918
Pickel VM, Reis DJ, Marangos PJ, Zomzely-Neurath C (1976) Immunocytochemical localisation of nervous system specific protein (NSP-R) in rat brain. Brain Res 105: 184–187
Royds JA, Davies-Jones GAB, Lewtas NA, Timperley WR, Taylor CB (1983) Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. J Neurol Neurosurg Psychiatry 46: 1031–1036
Scarna H, Steinberg R, Delafosse B, Debilly G, Mandrand B, Keller A, Pujol JF (1983) Neuron-specific enolase (NSE) in biological fluids: a marker of neuronal lesions. In: Peeters H (ed) Protides of the biological fluids. Pergamon Press, Oxford, pp 55–60
Schmechel DE, Marangos PJ (1983) Neuron specific enolase (NSE): specific cellular and functional marker for neurons and neuroendocrine cells. Curr Methods Cell Neurobiol 1: 1–62
Steinberg R, Gueniau C, Scarna H, Keller A, Worcel M, Pujol JF (1984) Experimental brain ischemia: neuron-specific enolase level in cerebrospinal fluid as an index of neuronal damage. J Neurochem 43: 19–24
Sulkava R, Viinikka L, Erkinjuntti T, Roine R (1988) Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer's disease. J Neurol Neurosurg Psychiatry 51: 549–551
Thompson EJ (1988) The CSF proteins: a biomedical approach. Elsevier, Amsterdam, pp 67–85
Tibbling G, Link H, Öhman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37: 385–390
Tomlinson BE, Corsellis JAN (1984) Ageing and the dementias. In: Hume Adams J, Corsellis JAN, Duchen LW (eds) Greenfield's neuropathology. Edward Arnold, London, pp 951–1025
Vermuyten K, Lowenthal A, Karcher D (1990) Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay. Clin Chim Acta 187: 69–78
Wakayama Y, Shibuya S, Kawase J, Sagawa F, Hashizume Y (1987) High neuron-specific enolase level of cerebrospinal fluid in the early stage of Creutzfeldt-Jakob disease. Klin Wochenschr 65: 798–801
Wallin A, Blennow K (1991) The pathogenetic basis of vascular dementia. Alzheimer Dis Assoc Disord 5: 91–102
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blennow, K., Wallin, A. & Ekman, R. Neuron specific enolase in cerebrospinal fluid: A biochemical marker for neuronal degeneration in dementia disorders?. J Neural Transm Gen Sect 8, 183–191 (1994). https://doi.org/10.1007/BF02260939
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260939